Ganges Securities Sharpens Its Appetite with Morton Foods Stake and CFCL Investmentla

Unknown Apr 02, 2026 1,000 Views

Ganges Securities Ltd has announced a two-pronged investment strategy, acquiring 670,000 equity shares of Morton Foods at ₹25 per share and earmarking up to ₹130 million for equity investment in CFCL, signaling a focused push into the FMCG and agri-input sectors. Morton Foods Share...

Morton Foods Share Purchase Details

* Acquired 670,000 equity shares in Morton Foods at ₹25 per share

* Total investment amounts to ₹16.75 million

* The acquisition enhances Ganges Securities' exposure to the fast-moving consumer goods segment

* Expected to strengthen the company’s food and retail vertical presence

CFCL Equity Investment Plan

* Ganges Securities to invest up to ₹130 million in equity shares of CFCL

* Investment aims to deepen presence in the agri-input and fertilizer business

* Strategic alignment with CFCL’s long-term growth plans and sector outlook

* Investment to be executed in tranches, subject to due diligence and regulatory norms

Strategic Rationale

* The two investments diversify Ganges Securities’ portfolio across high-growth, consumption-linked sectors

* Moves are in line with the company’s capital allocation framework focused on scalable, stable-growth businesses

* Aims to deliver long-term shareholder value through strategic equity participation

Market Implications

* Signals increased institutional confidence in both FMCG and agriculture sectors

* Could prompt rerating of Ganges Securities as a proactive investor in emerging consumption plays

* Investors expected to closely track financial outcomes from both investments over the next 2–3 quarters

About Ganges Securities Ltd

Ganges Securities Ltd is a non-banking financial company (NBFC) engaged in making strategic equity investments across sectors including food processing, agriculture, and financial services.

Sources: Exchange Filings, Company Press Releases, Market Sources

Stay Ahead – Explore Now! SBI Commits $1 Billion to Finance Sun Pharma’s Organon Deal